| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,250 | 7,050 | 18:17 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 11,000 | 500 | |||
| 9,500 | 175 | |||
| 8,550 | 450 | |||
| 7,050 | 1.377 | |||
| 7,000 | 70 | |||
| 6,900 | 70 | |||
| 6,800 | 701 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 631 | 6,450 | |||
| 70 | 6,400 | |||
| 70 | 6,300 | |||
| 1.377 | 6,250 | |||
| 70 | 6,200 | |||
| 300 | 4,900 | |||
| 700 | 4,740 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 4.279 | 0,790 | 3.382 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 06.10.2026 | 11:24:04 | 6,500 | 25 |
| Tagesumsatz Xetra | 0,000 0,00 % | 385 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 28.09. | 4basebio meldet starken Anstieg der Auftragseingänge bei sinkendem Umsatz | 40 | Investing.com Deutsch | ||
| 28.09. | 4basebio reports 210% rise in H1 sales orders amid revenue decline | 11 | Investing.com | ||
| 28.09. | 4basebio PLC H1 Loss Rises | 6 | RTTNews | ||
| 28.09. | 4BASEBIO PLC: 4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program | 9 | Cision News | ||
| 07.09. | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine | 703 | PR Newswire | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine
PR Newswire
LONDON, United Kingdom, September 07
4basebio... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 10:06 | BERENBERG stuft Biontech auf 'Buy' | dpa-AFX-Analyser | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Biontech auf "Buy" mit einem Kursziel von 140 US-Dollar belassen. Auf dem jährlichen Esmo-Krebskongress ab dem 23. Oktober in Madrid erwarte... ► Artikel lesen | |
| 08:15 | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | Small- & Micro Cap Investment | ||
| 13:06 | Arvinas Inc.: Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease | GlobeNewswire (Europe) | - Data showed improvements in an objective measure of impaired eye movement associated with Parkinson's disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers... ► Artikel lesen | |
| 08:24 | Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026 | Business Wire |
Operational launch of InVimmune, a subsidiary dedicated to differentiated approaches to in vivo cell therapy, with a first indication announced in oncology.
Appointment of Gilles Besin... ► Artikel lesen | |
| 13:06 | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics | GlobeNewswire (Europe) | Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005Cadrenal has received strong interest from potential strategic... ► Artikel lesen |